Years of sorafenib investigation in advanced non-small cell lung cancer: is there a ‘NExUS’ linking an unsuccessful treatment and a potentially active one?

Sorafenib, a multi-targeted receptor tyrosine-kinase inhibitor (TKI) with a supposedly predominant anti-angiogenic activity (inhibition of vascular endothelial growth factor receptor-2, -3 and platelet-derived growth factor ß), has been the subject of extensive clinical research in advanced non-small cell lung cancer (NSCLC).